CAR-T的翻译

In July 2016, three adult leukemia patients died in a trial of a new cellular-level medicine. Nicknamed CAR-T, this new treatment option was supposed to attack the malignant cells until they appeared to have vanished.

2016年7月，3名成年白血病患者死于一场临床试验，该实验使用了一种新的细胞层面的药物，叫做CAR-T（嵌合抗原受体T细胞免疫疗法），新疗法的治疗理念是攻击恶性细胞直到完全消灭它们。

Representatives from the sponsoring medical company Juno admit that cerebral edema is rather common in patients who have been given CAR-T treatments, as are immune system reactions and increased neurological toxicity.

来自医药公司的赞助商——朱诺的代表们承认，在接受CAR-T治疗的病人中，脑水肿的发生比较普遍，因为是免疫系统的反应增加了神经毒性。

High costs are viewed as one of the biggest drawbacks of the so-called CAR-T therapies under development by Novartis, Juno and Kite.

诺华制药、Juno和Kite正在研制中的所谓CAR-T疗法的最大缺点之一，就是被认为价格太高。